Empowering
Scientific
Discovery.
Revolutionizing Biotechnology with AI/ML
Accelerating Biotechnology Innovation
xBxBio is a pioneering biotechnology company that integrates life sciences with cutting-edge AI/ML technologies. By leveraging IP databases and High-Performance Computing, we are revolutionizing the industry with groundbreaking solutions in cardiac care, drug-drug interactions, and genetics. Our patent-pending Digital Twin technology could accelerate clinical trials by empowering personalized medicine, digitizing medical devices, and expediting drug discovery with significant cost savings and risk reduction.
Key areas of
conceptual focus
Cardiac Solutions
The platform's future ability to simulate the effects of different drugs on the heart will be instrumental in identifying promising compounds for treating heart disease.
The platform's advanced predictive models will help identify potential DDIs early in the development process, enhancing the safety profile of new drugs.
Drug-Drug Interactions
Genetics
The platform's comprehensive genetic databases will enable precise genetic testing, allowing targeted therapies to be developed based on individual genetic profiles.
Transforming Healthcare with xBxBio Platform
We're here to revolutionize the medical and biotech industries by blending the latest scientific advancements in life sciences with state-of-the-art software technology, including AI and ML.
IP Databases Galore:
We tap into vast intellectual property databases spanning chemistry, physics, biology, and mathematics.
Tackling Major Medical Challenges:
We aim to address pressing medical issues, focusing on heart health solutions, drug-drug interactions, and genetic research to make a positive impact medicine and patients'.
Accelerating Drug Discovery:
Supercharged Computing:
Our platform uses Cluster High-Performance Computing (HPC) to process complex data quickly and efficiently.
Pioneering Personalized Medicine:
Our patent-pending Digital Twin technology can accelerate trials by up to1 million times, significantly reducing costs and risks. Additionally, we are improving the functionality and efficiency of medical devices through digital transformation.
At xBxBio, we are confident in our ability to enhance personalized medicine, transform medical devices, and expedite drug discovery through the power of AI and ML. We are thrilled to be leading the charge towards a healthier future for all.
Founding Members:
Ken Bean, Bob Dysart, and Ashton Cowadia come together over a shared passion for cigars and football. They unite their diverse expertise to commercialize Bean's proprietary drug discovery technology.
Proof of Concept: Successful POC with a consortium of experts from Harvard, Yale, and MIT, showcasing the platform's potential.
Market Study: McKinsey & Company conducts a market study highlighting the large and growing opportunity for xBxBio.
Proprietary Patents: xBxBio files a global non-provisional patent application (PCT) and multiple provisional patents for its Digital Twin Model and Hologram Model technologies.
AWS Collaboration: Partnership with Amazon Web Services (AWS) and collaboration with Caylent, an AWS Preferred Consulting Strategic Partner.Regulated Industry Partnerships: Ongoing discussions with leading cardiac device companies and regulated partners in the medical devices and pharmaceuticals industries.
Holistic Approach:
The platform integrates chemistry, physics, biology, and mathmatics in an AI/ML-assisted four-dimensional platform at the atomic level.
Personalized Medicine: Utilizes advancements in Genomics (CRISPR, etc.) to personalize efficacy and minimize side effects.
New Applications:
The platform discovers new applications and parameters for existing drug portfolios, like finding new uses for migraine medicines such as Botox.
Digital Maturity in Life Sciences: xBxBio capitalizes on the booming digital health funding and emerging growth potential in digital and analytics (DNA) technologies.
Strategic Partnerships: Plans to expand the Proof of Concept, establish strategic partnerships, and drive global expansion.
Drug-Drug Interactions (DDI): Advanced predictive models will help identify potential DDIs early in the development process.
Genetic Profiling: Comprehensive genetic databases will enable precise genetic adjustments and targeted therapies.
Cardiac Solutions: The platform's future ability to simulate drug effects on the heart will help identify promising compounds for treating heart disease.
Discover Our Direction
Clear Path Forward